Analyzing Genmab A/S (NASDAQ:GMAB) & Lexaria Bioscience (NASDAQ:LEXX)
Analyzing Genmab A/S (NASDAQ:GMAB) & Lexaria Bioscience (NASDAQ:LEXX)
Genmab A/S (NASDAQ:GMAB – Get Rating) and Lexaria Bioscience (NASDAQ:LEXX – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.
Genmab A/S(纳斯达克：GMAB-GET评级)和利康生物(纳斯达克：Lexx-GET评级)都是医药公司，但哪一家是优势投资？我们将根据这两家公司的机构所有权、分析师建议、盈利能力、估值、风险、收益和股息的实力进行比较。
Risk and Volatility
风险和波动性
Genmab A/S has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.
Genmab A/S的贝塔系数为0.85，这意味着其股价的波动性比标准普尔500指数低15%。相比之下，Lexaria Bioscience的贝塔系数为0.04，这意味着其股价的波动性比标准普尔500指数低96%。
Institutional & Insider Ownership
机构与内部人持股
5.5% of Genmab A/S shares are owned by institutional investors. Comparatively, 9.4% of Lexaria Bioscience shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 9.6% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Genmab A/S公司5.5%的股份由机构投资者持有。相比之下，Lexaria Bioscience 9.4%的股份由机构投资者持有。Genmab A/S公司1.5%的股份由内部人士持有。相比之下，Lexaria Bioscience 9.6%的股份由内部人士持有。强大的机构持股表明，对冲基金、捐赠基金和大型基金管理公司相信，一只股票有望实现长期增长。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Genmab A/S | 38.42% | 17.12% | 15.37% |
| Lexaria Bioscience | -3,960.36% | -63.62% | -62.36% |
| 净利润率 | 股本回报率 | 资产回报率 | |
| Genmab A/S | 38.42% | 17.12% | 15.37% |
| Lexaria生物科学 | -3,960.36% | -63.62% | -62.36% |
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and price targets for Genmab A/S and Lexaria Bioscience, as reported by MarketBeat.com.
这是MarketBeat.com报道的Genmab A/S和Lexaria Bioscience最近的评级和目标价细目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genmab A/S | 1 | 7 | 2 | 0 | 2.10 |
| Lexaria Bioscience | 0 | 0 | 0 | 0 | N/A |
| 销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
| Genmab A/S | 1 | 7 | 2 | 0 | 2.10 |
| Lexaria生物科学 | 0 | 0 | 0 | 0 | 不适用 |
Genmab A/S presently has a consensus target price of $37.15, indicating a potential upside of 13.81%. Given Genmab A/S's higher possible upside, equities analysts clearly believe Genmab A/S is more favorable than Lexaria Bioscience.
Genmab A/S目前的共识目标价为37.15美元，表明潜在上行13.81%。鉴于Genmab A/S更有可能上行，股票分析师显然认为Genmab A/S比Lexaria Bioscience更有利。
Earnings & Valuation
收益与估值
This table compares Genmab A/S and Lexaria Bioscience's revenue, earnings per share and valuation.
该表格比较了Genmab A/S和Lexaria Bioscience的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genmab A/S | $1.35 billion | 15.92 | $478.57 million | $0.90 | 36.27 |
| Lexaria Bioscience | $720,000.00 | 20.58 | -$4.03 million | N/A | N/A |
| 总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
| Genmab A/S | 13.5亿美元 | 15.92 | 4.7857亿美元 | $0.90 | 36.27 |
| Lexaria生物科学 | $720,000.00 | 20.58 | -403万元 | 不适用 | 不适用 |
Genmab A/S has higher revenue and earnings than Lexaria Bioscience.
Genmab A/S的收入和收益高于Lexaria Bioscience。
Summary
摘要
Genmab A/S beats Lexaria Bioscience on 8 of the 11 factors compared between the two stocks.
Genmab A/S在比较两只股票的11个因素中有8个超过了Lexaria Bioscience。
About Genmab A/S
关于Genmab A/S
(Get Rating)
(获取评级)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Genmab A/S主要在丹麦开发用于治疗癌症和其他疾病的抗体疗法。该公司销售用于治疗多发性骨髓瘤(MM)患者的人类单抗DARZALEX；用于治疗甲状腺眼病的teprotomumab；用于治疗慢性淋巴细胞白血病(CLL)和多发性硬化症的人类单抗Ofatumurnab；以及用于晚期或转移性胃癌、食道癌和非小细胞肺癌的Amivantamab。其产品包括用于治疗MM、非MM血癌和AL淀粉样变性的daratumab；GEN1047；用于治疗宫颈癌、卵巢癌和实体瘤的tisotomab vedotin；用于治疗实体瘤的DuoBody-PD-L1x4-1BB和DuoBody-CD40x4-1BB；用于复发/难治性弥漫性大B细胞淋巴瘤和慢性淋巴细胞白血病的Epcoritamab；以及用于治疗血液系统恶性肿瘤的HexaBody-CD38和DuoHexaBody-CD37。该公司还开发处于第二阶段的产品，包括用于血管闭塞危机的Tecistamab；用于治疗霍奇金淋巴瘤和实体瘤的CamidanLumab Tesiine；用于治疗MM的JNJ-64007957和JNJ-64407564；用于治疗乳糜泻的PRV-015；用于治疗血友病A的MIM8；以及用于治疗多系统萎缩疾病的Lu AF82422。此外，它还有大约20个活跃的临床前项目。该公司与Seagen Inc.有商业许可和合作协议，共同开发tisotomab vedotin。它还与CureVac AG签订了研究和开发不同的基于信使核糖核酸的抗体产品的合作协议；AbbVie公司开发epcoritamab；与BioNTech公司、Janssen公司、Novo Nordisk A/S公司、Blink Biomedical SAS公司和Bolt BioTreateutics公司合作。Genmab A/S公司成立于1999年，总部设在丹麦哥本哈根。
About Lexaria Bioscience
关于Lexaria Bioscience
(Get Rating)
(获取评级)
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Lexaria Bioscience Corp.是一家生物技术公司。其专利药物传递技术DehyTECH通过促进有效的口服传递，改善了活性药物成分进入血液的方式。该公司的DehyTECH已经证明，与标准行业配方相比，大麻类药物和尼古丁的生物吸收增加了5-10倍，在某些情况下，大麻类药物的生物吸收增加了27倍，起效时间从1-2小时减少到几分钟，并掩盖了不想要的味道；还在评估口服抗病毒药物、非类固醇抗炎药(NSAID)、PDE5抑制剂和其他药物。脱氢TECH还可以有效地通过血脑屏障输送药物。它经营着一个获得许可的内部研究实验室，并拥有知识产权组合，在全球范围内已获得23项专利，约50项专利正在申请中。Lexaria Bioscience Corp.成立于2004年，总部设在加拿大基洛纳。
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genmab A/S日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genmab A/S和相关公司的最新新闻和分析师评级的每日简要摘要。